| Mar 17 2025 |
Telehealth Companies and Social Media Influencers May Face New FDA Laws |
Foley & Lardner LLP |
| Mar 17 2025 |
HHS Secretary Kennedy Directs FDA to Explore Rulemaking to Eliminate Self-Affirmed GRAS Pathway |
Keller and Heckman LLP |
| Mar 14 2025 |
Alert: New Mexico Is a Step Closer to Legalizing the Supervised Use of Psilocybin |
Womble Bond Dickinson (US) LLP |
| Mar 14 2025 |
Not Much of a Thank You: TRICARE Contractor Resolves $11M False Claims Act Liability for Known Cybersecurity Violations |
Tycko & Zavareei LLP |
| Mar 14 2025 |
McDermott+ Check-Up: March 14, 2025 |
McDermott Will & Schulte LLP |
| Mar 14 2025 |
IRS Roundup February 17 – March 14, 2025 |
McDermott Will & Schulte LLP |
| Mar 14 2025 |
Executive Order Signals Healthcare Price Transparency as a Priority |
Barnes & Thornburg LLP |
| Mar 14 2025 |
Paid Sick Leave in Michigan: Legislature Changes Course at the One-Yard Line |
Epstein Becker & Green, P.C. |
| Mar 13 2025 |
OCR Imposes $200,000 Penalty Against Oregon Health & Science University for HIPAA Right of Access Violations |
Hunton Andrews Kurth |
| Mar 13 2025 |
FDA’s Backup LDT Enforcement Method: Specimen Collection Kits |
Mintz |
| Mar 13 2025 |
Skin360 App Can’t Escape Scrutiny under Illinois Biometric Law |
Robinson & Cole LLP |
| Mar 13 2025 |
Proving Fraud is and Should Be Hard: Lessons from a Recent Medicare Advantage False Claims Act Decision |
Sheppard, Mullin, Richter & Hampton LLP |
| Mar 13 2025 |
Price Transparency: A Regulatory Priority |
McDermott Will & Schulte LLP |
| Mar 13 2025 |
HHS Scraps Richardson Waiver, Clearing Way for Faster Rulemaking |
Proskauer Rose LLP |
| Mar 13 2025 |
This Week in 340B: March 4 – 10, 2025 |
McDermott Will & Schulte LLP |
| Mar 12 2025 |
HHS Secretary Kennedy Directs FDA to Consider Eliminating Self-GRAS Determinations |
Keller and Heckman LLP |
| Mar 12 2025 |
Limits on Physician Noncompete Agreements: Navigating New State Laws and Legislation |
Epstein Becker & Green, P.C. |
| Mar 12 2025 |
Thinking of Selling Your Med Spa? Here Are Six Things to Do to Prepare |
Chuhak & Tecson, P.C. |
| Mar 12 2025 |
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs |
Foley & Lardner LLP |
| Mar 12 2025 |
Georgia Legislature Considering Substantial Overhaul to Medical Marijuana, Hemp Laws |
Bradley Arant Boult Cummings LLP |
| Mar 12 2025 |
EPA Extends Comment Period on Draft TSCA Risk Evaluation for DCHP |
Bergeson & Campbell, P.C. |
| Mar 11 2025 |
Even With FCC 1:1 Gone, the CMS 1:1 Rule is Still Standing |
Troutman Amin, LLP |
| Mar 11 2025 |
For Whom the Bell Tolls? The Impact of Wisconsin Bell v. United States ex rel. Todd Heath and United States v. Regeneron Pharmaceuticals Inc. on False Claims Act Litigation |
Womble Bond Dickinson (US) LLP |
| Mar 11 2025 |
Reminder: FDA Does, In Fact, Review DOF |
Sheppard, Mullin, Richter & Hampton LLP |
| Mar 11 2025 |
SuperValu Wins False Claims Act Case with a “No Harm, No Foul” Jury Verdict |
Sheppard, Mullin, Richter & Hampton LLP |
| Mar 11 2025 |
Changes on the Horizon for Long-Term Care Facilities |
Wilson Elser Moskowitz Edelman & Dicker LLP |
| Mar 11 2025 |
Federal Appeals Court Rules Against Doctor Seeking to Use Mushrooms to Aide Terminal Patients: How We Learned to Question the Rationale of the Controlled Substances Act |
Bradley Arant Boult Cummings LLP |
| Mar 11 2025 |
What Does the Phrase “Resulting From” Mean? Circuit Courts Split on Standard for Determining When an AKS Violation Is a False Claim |
Epstein Becker & Green, P.C. |
| Mar 11 2025 |
New York Health Data Requirements Potentially Ahead: Understanding the Newly Passed Health Information Privacy Act |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Mar 10 2025 |
Healthcare Preview for the Week of: March 10, 2025 [Podcast] |
McDermott Will & Schulte LLP |
| Mar 10 2025 |
Fashionably Late: Implementation of the New York Retail Worker Safety Act Delayed to June 2025 (US) |
Squire Patton Boggs (US) LLP |
| Mar 10 2025 |
Make America Healthy Again: New Executive Order Revisits Group Health Plan Price Transparency |
Jackson Lewis P.C. |
| Mar 10 2025 |
What Doesn't The DFPI Regulate? |
Allen Matkins Leck Gamble Mallory & Natsis LLP |
| Mar 9 2025 |
HHS Cuts Notice-and-Comment Rulemaking for Some Agency Actions |
Keller and Heckman LLP |
| Mar 7 2025 |
Colorado: Proposed Expanded Medical Care Transaction Oversight – What Providers and Investors Need to Know |
Foley & Lardner LLP |
